Clinical Trial

Teclistamab-Daratumumab in AL Amyloidosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-01; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07110844
Lead Sponsor Rajshekhar Chakraborty, MD
Collaborators: Janssen Pharmaceuticals
Conditions Amyloid Light-chain Amyloidosis
Enrollment 25 participants
Start Date 2025-11-07
Primary Completion 2031-10 (estimated)
Study Completion 2033-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-13